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Abstract
In a recent summary of integrase sequences, primary integrase inhibitor mutations were rare. In a
review of integrase inhibitor-naïve Australian HIV-1 sequences, primary mutations were not
identified, although the accessory mutation G140S was detected. A link with previous antiretroviral
therapy, intra-subtype B divergence across the integrase gene and transmission of integrase
polymorphisms were also noted. Based on these findings, we would recommend ongoing
surveillance of integrase mutations, and integrase region sequencing for patients prior to
commencement of integrase inhibitors.
Correspondence
We congratulate Rhee and colleagues for their extensive
review of the natural variation of HIV-1 integrase in 1500
integrase sequences from B and non-B HIV-1 subtypes [1].
This study provides significant insights into integrase
inhibitor (INIs) resistance mutations and polymor-
phisms, and forms an essential component in guiding
therapeutic decisions. This has become even more imper-
ative since the licensing of raltegravir (RAL) for the treat-
ment of antiretroviral (ARV)-experienced HIV-1 infected
patients, following the definitive BENCHMRK 1 and 2 tri-
als [2,3].
In both BENCHMRK trials, treatment failure was associ-
ated with the selection of signature, or primary, INI muta-
tions. These occur in one of two main pathways, either
N155H or Q148H/K/R. A possible alternative and third
pathway, Y143R/C, also exists. Primary INI mutations
were detected by Rhee et al. in their review of the Stanford
HIV Database in only 3 isolates (each with a single pri-
mary INI mutation N155H, Q148H and Q148K). We are
aware of possibly two additional isolates, one from an
Australian isolate bearing N155H in an INI-naïve patient
(GenBank Accession No. AF042104) and a second resist-
ant isolate published by Myers et al. [4]. Therefore,
although primary mutations remain rare in INI treatment-
naïve individuals, their occurrence suggests that IN
sequencing should be considered in all patients prior to
INI therapy.
The role of accessory mutations in INI resistance is less
clear. It is known that pathway-specific accessory muta-
tions augment INI resistance in the presence of the pri-
mary mutations. However, the phenotypic effect of most
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isolated single accessory mutations (i.e. T97A, V151I,
G163R, I203M and S230N) remains unknown. In con-
trast, isolated L74A/I/M has no effect on in vitro resistance
while G140S is associated with an in vitro 5–10 fold
decrease in susceptibility [4] (Personal communication
with Merck Sharp & Dohme). This mutation is not only
responsible for partial RAL resistance but also restores
viral fitness when combined with the Q148R/H mutation
[5]. G140S was not documented by Rhee et al. in their
review [1]. However, in a small study conducted at West-
mead Hospital, Sydney, Australia, G140S was detected in
2 INI-naïve patients, as were the other accessory muta-
tions: L74I/M (n = 8), T97A (n = 2), V151I (n = 3) and
I203M (n = 4). In this study, plasma from 133 INI-naïve
patients were sequenced (GenBank Accession Numbers
FJ554674–FJ554806) across integrase. Most sequences
belonged to HIV-1 subtype B (n = 109). The remaining 25
sequences include subtype A (n = 4); subtype C (n = 8);
subtype G (n = 4), CRF02_AG (n = 3), CRF01_AE (n = 2)
and CRF33_01B (n = 3). Using the same HIV-1 subtype B
consensus sequence as Rhee and colleagues, similar sub-
type-specific consensus residues were detected. For the
newly described CRF33_01B subtype (not studied by
Rhee et al.) several polymorphisms were detected in all
sequences i.e. V31I, T112V, T125A [6]. Although other
residues were similar to other non-B subtypes (varying
from the consensus B subtype), no firm conclusions can
be made because the number of CRF33_01B sequences
studied was small.
The influence of prior ARV therapy (not including INIs)
was not addressed by Rhee et al. Interestingly, we found
that previous ARV therapy was associated with greater IN
divergence (the mean intra-subtype B divergence was
5.1% +/- 0.17 in 59 samples from treatment-experienced
patients compared to a mean of 3.8% +/- 0.18 in 50 treat-
ment-naïve samples; p < 0.01). This finding suggests that
ARV-induced changes in other parts of the HIV-1 genome
may be linked to integrase polymorphisms. This is sup-
ported by data that has detected several integrase poly-
morphisms (e.g. M154I, V165I and M185L) positively
associated with specific RT mutations (F227L and T215Y)
in samples from treated individuals [7]. We were unable
to find any evidence to suggest this co-evolution at the IN
and RT sites, probably as a consequence of our small sam-
ple size. It still remains unknown whether the efficacy of
INIs is affected by previous ARV therapy selection pres-
sure. However, both G140S mutations in our study
occurred in samples from previously ARV-treated individ-
uals, suggesting that previous therapy may result in
reduced INI efficacy, and further supporting IN sequenc-
ing in patients contemplating INI therapy initiation.
A further question not addressed by Rhee and colleagues
was the potential transmission of IN polymorphisms. In
our study, three subtype B-infected patients (GenBank
Accession Numbers FJ554692; FJ554718; FJ554739) were
known to have acquired their infection from the same
source. These samples all had IN sequencing performed
on plasma, cultured isolates and peripheral blood mono-
nuclear cells. Several IN polymorphisms (S24N, D25E,
T112I, S119P, T125A, K136Q, V201I, L234I and S283G)
were present in all three patients, suggesting that they
were readily transmitted. Interestingly, the sequences did
not vary by more than 0.2%, suggesting little sequence
variation between the various HIV-1 "compartments".
In conclusion, ongoing surveillance of integrase inhibitor
polymorphisms is important, including in non-subtype B
viruses. We suggest that IN sequencing should be under-
taken in all patients prior to INI commencement to enable
further elucidation of resistance pathways, and determi-
nation of the significance of subtype-specific polymor-
phisms in both ARV-naïve and experienced individuals.
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